Pacific Bioscience Laboratories, Inc. v. Pretika Corp.

760 F. Supp. 2d 1061, 2011 U.S. Dist. LEXIS 3565, 2011 WL 65950
CourtDistrict Court, W.D. Washington
DecidedJanuary 10, 2011
DocketCase C10-0231JLR
StatusPublished
Cited by17 cases

This text of 760 F. Supp. 2d 1061 (Pacific Bioscience Laboratories, Inc. v. Pretika Corp.) is published on Counsel Stack Legal Research, covering District Court, W.D. Washington primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Pacific Bioscience Laboratories, Inc. v. Pretika Corp., 760 F. Supp. 2d 1061, 2011 U.S. Dist. LEXIS 3565, 2011 WL 65950 (W.D. Wash. 2011).

Opinion

ORDER GRANTING MOTION TO STAY

JAMES L. ROBART, District Judge.

I. INTRODUCTION

This matter is before the court on Defendant Pretika Corporation’s (“Pretika”) motion to stay this litigation pending the ex parte reexamination of numerous claims of United States Patent No. 7,320,691 (“the '691 patent”) by the United States Patent and Trademark Office (“USPTO”). (Mot. (Dkt. # 29) & Praecipe (Dkt. # 31).) The court has considered Pretika’s motion, all submissions filed in support and opposition to the motion, as well as the pleadings on file. The court also heard the argument of counsel on January 7, 2011. For the reasons stated below, the court GRANTS Pretika’s motion for a stay (Dkt. #29).

II. FACTUAL AND PROCEDURAL BACKGROUND

This is a patent infringement case. Plaintiff Pacific Bioscience Laboratories, Inc. (“PBL”) develops and markets sonic facial brush devices under its Clarisonic line of products. (Resp. (Dkt. # 34) at 2). Pretika markets and sells an allegedly competing device known as the SonicDermabrasion Facial Brush. (See Mot. at 2.) PBL alleges that Pretika’s SonieDermabrasion Facial Brush infringes its '691 patent. (Compl. (Dkt. # 1) at ¶¶ 14-23.)

The application that ultimately issued as the '691 patent was filed on January 15, 2003. (Mot. at 3.) In December 2006, PBL asserts that it formally notified Pretika that PBL owned several utility patent applications having claims that read on the Pretika SonicDermabrasion device. (Resp. at 4.) On January 22, 2008, the USPTO issued the '691 patent, which has been assigned to PBL. (Compl. at ¶ 11.) However, it was not until February 8, 2010, more than three years following PBL’s first notification to Pretika of alleged infringing activity, and nearly two years following the issuance of the '691 patent, that PBL filed suit for patent infringement against Pretika. (See Compl.) *1063 PBL did not serve its complaint on Pretika until March 12, 2010. (Affid. of Serv. (Dkt. # 7).)

Pretika sought reexamination of the '691 patent on May 14, 2010 (approximately two months following service of the complaint), and again on June 25, 2010. (See Resp. at 7, n. 1 & n. 2.) However, in both of these instances, Pretika’s submissions were rejected by the USPTO because they did not comply with certain requirements. 1 (Id.) Nevertheless, Pretika promptly amended its submissions, and in August 2010, submitted a facially complete reexamination request to the USPTO. (Resp. at 7.) On September 30, 2010, the USPTO granted Pretika’s request for ex parte reexamination of the '691 patent. (Mot. at 1; USP-TO Order (Dkt. # 28-1).) One week later, on October 7, 2010, Pretika filed its present motion seeking a stay of these proceedings.

In its order granting Pretika’s reexamination request, the USPTO found that pri- or art that had never been cited to or considered by the USPTO during the prosecution of the original patent application at issue here raised “[a] substantial new question of patentability.” (See USPTO Order at 4.) The reexamination order encompasses all of the claims of the '691 patent that PBL asserts against Pretika in this litigation. (Id.; Mot. at 1.)

The parties have engaged in some, but not extensive discovery. Both sides have served and answered interrogatories and requests for production. (Resp. at 5.) Pretika propounded only nine discovery requests. (Reply (Dkt. # 39) at 5.) Both sides have exchanged invalidity and infringement contentions, as well as claim terms for construction during the Mark-man hearing. (Resp. at 5.) Pretika’s invalidity contentions include the same allegations set forth in the reexamination requests. (Reply at 5.) Pretika also issued two third-party subpoenas related to the prior art identified in the reexamination request, as well as to Pretika’s investigation of possible inequitable conduct on the part of PBL. (Reply at 5.) No party has scheduled any depositions. (Id.) The Markman hearing has not yet been conducted, and no briefing related to the hearing has been filed. The trial is not set to commence until November 14, 2011. (See Sched. Order (Dkt. # 23).)

III. ANALYSIS

A district court has the discretion to stay judicial proceedings pending reexamination of a patent by the USPTO. See Amado v. Microsoft Corp., 517 F.3d 1353, 1358 (Fed.Cir.2008); Ethicon, Inc. v. Quigg, 849 F.2d 1422, 1426-27 (Fed.Cir. 1988). In determining whether to grant a stay pending reexamination, the court considers: (1) whether a stay will simplify the issues in question and the trial of the case, (2) whether discovery is complete and whether a trial date has already been set, and (3) whether a stay will unduly prejudice or present a clear tactical disadvantage to the non-moving party. Wre-Hol, LLC v. Pharos Science & Applications, No. C09-1642 MJP, 2010 WL 2985685, at *2 (W.D.Wash. July 23, 2010).

A. Simplification of the Issues

Pretika asserts that, based on the strength of the prior art, there exists a high likelihood that the USPTO will cancel or significantly amend the claims at issue *1064 in the '691 patent. (See Mot. at 9.) Pretika also cites statistics published by the USP-TO which demonstrate that in over 75% of cases in which reexamination requests are granted, claims are either changed or can-celled. (M)(eiting Scott Decl. (Dkt. #30 Ex. 13.)) Pretika argues that because it is likely that at least some of the claims at issue here will be cancelled or amended, the simplification factor weighs in favor of a stay. In response, PBL asserts that to satisfy this factor the outcome of a reexamination must finally resolve all issues in the litigation. (Resp. at 9.) Therefore, in PBL’s view, a stay is not warranted because “[t]here is a nearly one-in-four chance that all of the claims of the '691 patent will emerge from reexamination unchanged,” and an only 12% chance that all of the claims will be cancelled. (Id.) (citing Harlow Deck (Dkt. # 36 Ex. H).)

First, the court rejects PBL’s assertion that satisfaction of the simplification factor requires the elimination of all issues in the litigation. 2 If PBL’s position were correct, then based on the statistics PBL cites, this factor could never be satisfied, and that reality is not reflected in the case law. Stays have been granted in numerous cases where reexamination would likely simplify, but not eliminate, all issues in the litigation. See e.g. Implicit Networks, Inc. v. Advanced Micro Devices, Inc., No. C08184JLR, 2009 WL 357902, at *2 (W.D.Wash. Feb.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
760 F. Supp. 2d 1061, 2011 U.S. Dist. LEXIS 3565, 2011 WL 65950, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pacific-bioscience-laboratories-inc-v-pretika-corp-wawd-2011.